en · de · es · fr · pt
cardarine-notes.peptides3626.com › News › Regulatory Status And Detection Context — Common Mistakes

Regulatory Status And Detection Context — Common Mistakes

By Editorial Desk · published 2026-04-15 · last reviewed 2026-05-03 · News

nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.

Regulatory Status and Detection Context

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Mechanism and Research Context

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

Cardarine at a glance

PropertyValueNotes
Regulatory statusNot approved for human therapeutic useNo marketing authorization identified in major jurisdictions.
Anti-doping classPPARδ agonist; hormone and metabolic modulatorsListed on the WADA Prohibited List.
Common test matrixUrineAlso blood and tissue in research settings.
Typical analytical methodLC-MS/MSTargets parent compound and metabolites.
Major safety signalTumor findings in rodentsHuman relevance not established; limited human data.

Identity and Regulatory Status

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Related pages on this site

Detection and Regulatory Landscape

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Further detail

Mycorrhizal Associations: The Web Resource Comprehensive illustrations and lists of mycorrhizal and nonmycorrhizal plants and fungi Mycorrhizas – a successful symbiosis Biosafety research into genetically modified barley International Mycorrhiza Society International Mycorrhiza Society MycorWiki a portal concerned with the biology and ecology of ectomycorrhizal fungi and other forest fungi.

==== Use of booby-trapped devices ==== Experts warned the 2024 Lebanon electronic device attacks potentially violated international humanitarian law. Josep Borrell, the European Union's High Representative for Foreign Affairs and Security Policy, questioned the legality of the pager attacks due to their high collateral damage among civilians, including the deaths of children. Jeanine Hennis-Plasschaert, the United Nations Special Coordinator for Lebanon, also raised concerns that the attacks were illegal. Belgian deputy prime minister Petra De Sutter went further, calling it a "terror attack". Volker Turk, the UN human rights chief, stated, "International humanitarian law prohibits the use of booby-trap devices in the form of apparently harmless portable objects". Booby traps are mostly outlawed under the Protocol on Mines, Booby-Traps and Other Devices ("Amended Protocol II") of the Convention on Certain Conventional Weapons, to which Israel is a party. Article 7, paragraph 2 of Amended Protocol II prohibits the use of "booby-traps or other devices in the form of apparently harmless portable objects which are specifically designed and constructed to contain explosive material." The rules of engagement of some countries, such as the United Kingdom, also ban explosive devices disguised as harmless items.

After a vascular injury occurs, platelets are activated by locally exposed collagen (glycoprotein (GP) VI receptor), locally generated thrombin (PAR1 and PAR4 receptors), platelet-derived thromboxane A2 (TxA2) (TP receptor) and ADP (P2Y1 and P2Y12 receptors) that is either released from damaged cells or secreted from platelet dense granules. The von Willebrand factor (VWF) serves as an essential accessory molecule. In general terms, platelet activation initiated by agonist takes to a signaling cascade that leads to an increase of the cytosolic calcium concentration. Consequently, the integrin αIIbβ3 is activated and the binding to fibrinogen allows the aggregation of platelets to each other. The increase of cytosolic calcium also leads to shape change and TxA2 synthesis, leading to signal amplification.

Sources: en.wikipedia.org

Supporting material

=== First World Cup appearance (1958–1962) === Colombia entered World Cup qualifying for the first time in 1961, meeting Peru over two legs under Argentine manager Pedernera, who had remained in the country after El Dorado as a coach. A 1–0 win in Bogotá on 30 April 1961 was followed by a 1–1 draw in Lima a week later, and Colombia advanced to the 1962 FIFA World Cup in Chile. Drawn in Group 1 with Uruguay, the Soviet Union and Yugoslavia, Colombia lost their opening match to Uruguay 2–1 on 30 May and were beaten 5–0 by Yugoslavia on 7 June, finishing bottom of the group with a single point from three games and five goals scored against eleven conceded. Their remaining fixture, however, produced one of the tournament's defining results. Facing the reigning European champions at the Estadio Carlos Dittborn in Arica on 3 June before a crowd of 8,040, with Brazilian referee João Filho officiating, Colombia trailed 3–0 inside eleven minutes to goals from Valentin Ivanov in the eighth and eleventh minutes either side of an Igor Chislenko strike in the tenth. Germán Aceros reduced the deficit in the 21st minute, but Viktor Ponedelnik restored a three-goal lead in the 56th. With twenty minutes remaining, Marcos Coll scored directly from a corner in the 68th minute, the ball creeping in at the near post past Lev Yashin — the only goal scored direct from a corner in World Cup history, and conceded by a goalkeeper then widely regarded as the world's finest. Antonio Rada struck in the 72nd minute and Marino Klinger completed the recovery late on to secure a 4–4 draw.

Column C is the original assignment by Corey and Pauling. Column K is that of Koltun's patent. Column J is the color scheme used by the molecular visualizer Jmol. Column R is the scheme used by Rasmol; when two colors are shown, the second one is valid for versions 2.7.3 and later. Column P consists of the colors in the PubChem database managed by the United States National Institute of Health. All colors are approximate and may depend on the display hardware and viewing conditions.

In another direction, Morris et al reported the use of GdL as a 'molecular trigger' to predict and control the order of gelation. Chirality also plays an essential role in gel formation, and even changing the chirality of a single amino acid from its natural L-amino acid to its unnatural D-amino acid can significantly impact the gelation properties, with the natural forms not forming gels. Furthermore, aromatic interactions play a key role in hydrogel formation as a result of π- π stacking driving gelation, shown by many studies.

Hydrostatic skeletons are flexible cavities within an animal that provide structure through fluid pressure, occurring in some types of soft-bodied organisms, including jellyfish, flatworms, nematodes, and earthworms. The walls of these cavities are made of muscle and connective tissue. In addition to providing structure for an animal's body, hydrostatic skeletons transmit the forces of muscle contraction, allowing an animal to move by alternating contractions and expansions of muscles along the animal's length.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Why is cardarine prohibited in sport?

It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.

What is known about cardarine and cancer?

Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Network